Merck announced that the U.S. Food and Drug Administration (FDA) has
approved an expanded indication for KEYTRUDA® (pembrolizumab),
the company’s anti-PD-1 (programmed death receptor-1) therapy, to
include the first-line treatment of patients with unresectable or
metastatic melanoma. This approval marks the second FDA-approved
indication in advanced melanoma for KEYTRUDA, which is now the first
anti-PD-1 therapy approved for previously untreated advanced melanoma
patients regardless of BRAF status. The FDA-approved dose of KEYTRUDA is
2 mg/kg every three weeks
KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that works
by increasing the ability of the body’s immune system to help detect and
fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its
ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may
affect both tumor cells and healthy cells.
For details enter clinical trial of KEYTRUDA visit here